

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
12 April 2024 :: Issue 746
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives



Meningitis

[In world first, Nigeria introduces new 5-in-1 vaccine against meningitis](#)

Health workers rollout immunization campaign aiming to reach one million people

12 April 2024 News release Geneva

In a historic move, **Nigeria has become the first country in the world to roll out a new vaccine (called Men5CV)** recommended by the World Health Organization (WHO), which protects people against five strains of the meningococcus bacteria. The vaccine and emergency vaccination activities are funded by Gavi, the Vaccine Alliance, which funds the global meningitis vaccine stockpile, and supports lower-income countries with routine vaccination against meningitis.

Nigeria is one of the 26 meningitis hyper-endemic countries of Africa, situated in the area known as the African Meningitis Belt. Last year, there was a 50% jump in annual meningitis cases reported across Africa...

The revolutionary new vaccine offers a powerful shield against the five major strains of the meningococcal bacteria (A, C, W, Y and X) in a single shot. All five strains cause meningitis and blood poisoning. This provides broader protection than the current vaccine used in much of Africa, which is only effective against the A strain.

The new vaccine has the potential to significantly reduce meningitis cases and advance progress in defeating meningitis. This is especially important for countries like Nigeria where multiple serogroups are prevalent. **The new vaccine uses the same technology as the meningitis A conjugate vaccine (MenAfriVac®), which wiped out meningococcal A epidemics in Nigeria...**

This new multivalent conjugate vaccine was 13 years in the making and was based on a **partnership between PATH and the Serum Institute of India.** Financing from the UK government's Foreign, Commonwealth and Development Office was critical to its development.

In July 2023, WHO prequalified the new Men5CV vaccine (which has brand name MenFive®) and in October 2023 issued an official recommendation to countries to introduce the new vaccine. Gavi allocated resources for the Men5CV rollout in December 2023, which is currently available for outbreak response through the emergency stockpile managed by the International Coordinating Group (ICG) on Vaccine Provision, while roll-out through mass preventive campaigns is expected to start in 2025 across countries of the Meningitis Belt...



Featured Journal Content

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 12 Apr 2024]

[The impact of conflict on infectious disease: a systematic literature review](#)

Authors: Valia Marou, Constantine I. Vardavas, Katerina Aslanoglou, Katerina Nikitara, Zinovia Plyta, Jo Leonardi-Bee, Kirsty Atkins, Orla Condell, Favelle Lamb and Jonathan E. Suk

Citation: Conflict and Health 2024 18:27

Content type: Review Published on: 8 April 2024

...Findings

Our review identified **51 studies covering AIDS, Hepatitis B, Tuberculosis, Cholera, Coronavirus 2, Ebola, Poliomyelitis, Malaria, Leishmaniasis, Measles, Diphtheria, Dengue and Acute Bacterial Meningitis within conflict settings in Europe, Middle East, Asia, and Africa since October 2023.**

Key factors contributing to disease emergence and transmission in conflict situations included population displacement, destruction of vital infrastructure, reduction in functioning healthcare systems and healthcare personnel, **disruption of disease control programmes (including reduced surveillance, diagnostic delays, and interrupted vaccinations)**, reduced access by healthcare providers to populations within areas of active conflict, increased population vulnerability due to limited access to healthcare services, and disruptions in the supply chain of safe water, food, and medication.

To mitigate these infectious disease risks **reported preparedness and response strategies included both disease-specific intervention strategies as well as broader concepts such as the education of conflict-affected populations through infectious disease awareness programmes**, investing in and enabling health care in locations with displaced populations, intensifying immunisation campaigns, and ensuring political commitment and intersectoral collaborations between governments and international organisations.



Featured Journal Content

The Lancet

Apr 13, 2024 Volume 403 Number 10435 p1419-1512

<https://www.thelancet.com/journals/lancet/issue/current>

Health Policy

[A legal mapping of 48 WHO member states' inclusion of public health emergency of international concern, pandemic, and health emergency terminology within national emergency legislation in responding to health emergencies](#)

Clare Wenham, Liam Stout

Open Access

Summary

WHO has determined a public health emergency of international concern (PHEIC) seven times, and beyond this nomenclature declared COVID-19 to be a pandemic. Under the International Health Regulations (IHR), and through their operationalisation in the joint external evaluation (JEE), **governments are urged to create suitable legislation to be able to enact a response to a public health emergency.** Whether the pandemic declaration had a greater effect than a PHEIC in encouraging governments to act, however, remains conjecture, as there is no systemic analysis of what each term means in practice and whether either has meaningful legal implications at the national level.

We undertook a legal scoping review to assess the utilisation of PHEIC and pandemic language within national legislation in 28 WHO member states. Data were collected from national websites, JEE reviews, COVID Analysis and Mapping of Policies Tool, Natlex, and Oxford

Compendium of National Legal Responses to COVID-19. We found that only 16% of countries have any reference to the PHEIC in national legislation and 37.5% of countries reference the term pandemic.

This finding paints a weakened picture of the IHR and PHEIC mechanisms. Having such legalese enshrined in legislation might enhance the interaction between WHO determining a PHEIC or declaring a pandemic and resulting action to mitigate transnational spread of disease and enhance health security. **Given the ongoing negotiations at WHO in relation to the amendments to the IHR and creation of the pandemic accord, both of which deal with this declaratory power of the PHEIC and pandemic language, negotiators should understand the possible implications of any changes to these proclamations at the national level and for global health security.**

[Excerpt from article]

Discussion

... **Overall, our findings remain alarming for global health governance.** We recognise the need for further analysis of the context in which current PHEIC or pandemic language is used and PHEIC's legal standing within existing provisions. **We also see the need for further analysis of the normative power of the PHEIC and pandemic language in policy documents, national guidelines, and within governments,** which could be done as a follow-on project. Our research begins the process of quantifying the extent to which a PHEIC determination or pandemic declaration is relevant to national health responses. Existing literature or anecdotal assessment frequently asserts their significance, yet our findings suggest otherwise.

This observation raises key questions as WHO is amid the process of amendments to the IHR, including Article 12, and the ongoing parallel process within the Intergovernmental Negotiating Body to negotiate a pandemic agreement. To succeed, WHO must recognise the apparent legal weakness of the PHEIC mechanism and pandemic declaration in spurring national responses before agreeing to related amendments and developing new binding terminology in relation to a pandemic emergency.

One key area for consideration is exactly how to combine the existing PHEIC and new legal language concerning a pandemic. Recognising the limitations of the PHEIC and pandemic terminology will help ensure revisions address underlying problems and promote consequential change. **Otherwise, WHO risks creating legal mechanisms with restricted application and experiencing a repeat of the delayed responses by states to future health threats.** At the same time, WHO must preserve the existing normative power of the PHEIC and protect the decision making process from erosion by political and economic interests.²

Reliance on this normative power makes such protection necessary, particularly when the PHEICs' legal significance in national legislation remains doubtful. The same applies to any future pandemic agreement. **Instilling accountability in mechanisms to maximise national engagement will strengthen global health governance, promote rapid response, and ultimately mitigate the spread of emerging pathogens.** Understanding the implications of the language used in legislation and what it might mean in practice is important.

.....

[**WHO Member States agree to resume negotiations aimed at finalizing the world's first pandemic agreement**](#)

28 March 2024 *News release*

WHO Member States agreed to resume negotiations aimed at finalizing a pandemic agreement during 29 April to 10 May. The decision came at today's end of two weeks of

intensive country-led discussions on critical subjects aimed at making all countries of the world better prepared for, and able to effectively and equitably respond to, future pandemics.

This [ninth meeting](#) of the [Intergovernmental Negotiating Body](#) (INB9) started on 18 March and ended today. Government negotiators discussed all articles from the [draft agreement](#), including adequate financing for pandemic preparedness, equitable access to medical countermeasures needed during pandemics and health workforce strengthening.

“Our Member States are fully aware of how important the pandemic agreement is for protecting future generations from the suffering we endured through the COVID-19 pandemic,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “I thank them for their clear commitment to finding common ground and finalizing this historic agreement in time for the World Health Assembly.”

Next month’s resumption of INB9 will be a critical milestone ahead of the Seventy-seventh World Health Assembly, starting 27 May 2024, at which Member States are scheduled to consider the proposed text of the world’s first pandemic agreement for adoption...



G20 – Global Health

[Open letter from the biopharmaceutical industry to G20 Ministers in support of the advancement of the G20 Health Agenda](#)

Statement 9 April 2024

IFPMA, [Interfarma](#), [FIFARMA](#)

[Excerpt]

Biopharmaceutical industry support for G20 health priorities

The biopharmaceutical industry significantly contributes in many ways towards G20 HWG priorities, including in the areas of Immunization, Pandemic Preparedness and Response (PPR) (including equitable access), Anti-Microbial Resistance (AMR), Neglected Tropical Diseases (NTDs), Climate Change, and Women’s Health. In the below sections, we set out our current engagement and 11 key proposals that would complement the G20 health agenda.

:: Across all mentioned areas, we call on the G20 to preserve health innovation enablers^[1] (e.g. intellectual property framework) in policies and programs in G20 countries and worldwide. These enablers fundamentally underpin legal security to enhance the potential for increased trade, investments, and voluntary collaborations^[2], including technology transfer^[3] in G20 countries. Innovation is a critical driver for healthy and vibrant economies and societies, and it is key to ensure sustainable government funding and financing for innovation moving forward.

Strengthening immunization policies

In 2024, we celebrate the 50th anniversary of the Essential Programme of Immunization, highlighting its success in reducing child mortality by 80% and saving over a billion lives. This achievement reflects significant milestones, including the eradication of smallpox and the development of vaccines for diseases like measles, mumps, rubella, and hepatitis, among others. The renewed ambition on polio and introduction of vaccines against HPV and malaria in recent years continues this legacy of innovation and public health improvement.

The COVID-19 pandemic has underscored the critical impact of infectious diseases on healthcare systems and the global economy, highlighting the importance of vaccines in preventing diseases across all ages. Current challenges, such as the resurgence of measles and the “triple-demic” of COVID-19, influenza, and RSV, emphasize the ongoing battle against vaccine-preventable diseases amidst demographic shifts, noncommunicable diseases, AMR, climate change, and growing rates of vaccine hesitancy, disinformation and increasing mistrust in science.

To address these challenges, a life-course approach to vaccination programs, with expansion into adulthood, is a cost-effective public health intervention, crucial for promoting health and well-being, reducing disease burden, and enhancing economic resilience.[4],[5] The biopharmaceutical industry’s innovation in developing 260 vaccine candidates across all diseases[6],[7] demonstrates its long-standing commitment to global health. Governments are urged to prioritize vaccination throughout life, recognizing its socioeconomic benefits and investing in comprehensive immunization programs to serve as primary health care (PHC) and universal health coverage (UHC) foundation and prepare for future health challenges, aligning with the WHO’s Immunization Agenda 2030 and the UN SDGs.

:: We call on G20 to adopt a prevention-first strategy, recognize the broader socio-economic value of adult immunization programs and enable adequate and sustainable budget allocations for life-course immunization inclusion and implementation. These implementation efforts should include building acceptance and demand, garnering trust and public confidence in the safety and efficacy of vaccination, enhancing infrastructures to increase access while improving health system resilience and community protection, recovery from the pandemic, and to help prepare for future health emergencies...

.....
.....

Polio – PHEIC

[Polio this week as of 10 Apr 2024 - GPEI](#)

Headlines

No new digest content identified.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Afghanistan: one WPV1 case and five positive environmental samples
- Pakistan: 12 WPV1-positive environmental samples
- Liberia: one cVDPV2 positive environmental sample
- Madagascar: five cVDPV1 positive environmental samples

.....

[Statement following the Thirty-eighth Meeting of the IHR Emergency Committee for Polio](#)

8 April 2024 *Statement*

[Excerpts; Editor’s text bolding]

The thirty-eighth meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened by the WHO Director-General on 20 March 2024 with committee members and advisers meeting via video conference with affected countries, supported by the WHO Secretariat. The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV) in the context of the

global target of interruption and certification of WPV1 eradication by 2026 and interruption and certification of cVDPV2 elimination by 2028. Technical updates were received about the situation in the following countries: Afghanistan, Angola, Côte d'Ivoire, Indonesia, Liberia, Mozambique, Pakistan, Sierra Leone, South Sudan and Sudan...

...*Conclusion*

The Committee unanimously agreed that the risk of international spread of poliovirus still remains a Public Health Emergency of International Concern (PHEIC) and recommended the extension of Temporary Recommendations for a further three months.

The Committee considered the following factors in reaching this conclusion:

Ongoing risk of WPV1 international spread:

Based on the following factors, the risk of international spread of WPV1 remains:

- **re-infection of epidemiologically critical areas and historical reservoirs like Karachi and the Quetta Block in Pakistan and Kandahar in Afghanistan represents a significant risk to the gains made during the last 18 months;**
- the actual spread of WPV1 lineages seen predominantly in Afghanistan in 2022 now being detected in Pakistan in 2023 and 2024;
- high-risk mobile populations in Pakistan represent a specific risk of international spread to Afghanistan in particular, compounded by the large number of returnees from Pakistan into a number of provinces of Afghanistan;
- **the large pool of unvaccinated 'zero dose' and underimmunized children in southern Afghanistan constitutes a major risk;**
- some areas of Afghanistan still only allow site to site or mosque to mosque immunization response, which has been shown to be less effective than the house to house modality;
- although it is likely transmission of WPV1 has been interrupted in Malawi and Mozambique, the route from Pakistan to Africa remains unknown;
- pockets of insecurity in the remaining endemic transmission zones; and
- any setback in Afghanistan poses a risk to the programme in Pakistan due to high population movement.

Ongoing risk of cVDPV international spread:

Based on the following factors, the risk of international spread of cVDPV2 appears to remain high:

- the outbreak of cVDPV1 in and ongoing high transmission of cVDPV2 in eastern Democratic Republic of the Congo and cVDPV2 in north-western Nigeria, which have caused international spread to neighboring countries;
- ongoing cross border spread including into newly re-infected countries such as Angola, Liberia, Senegal and Sierra Leone;
- the new emergence of cVDPV2 in South Sudan, which whole genome sequencing (WGS) indicates the origin of the virus is novel OPV2, despite that the vaccine has never been used in the country. However, South Sudan shares many land borders with countries that have used novel OPV2 in the years 2022 – 2023, including Ethiopia, Kenya, Uganda, DR Congo and CAR;
- **the ever-widening gap in population intestinal mucosal immunity in young children since the withdrawal of OPV2 in 2016 and consequently high concentration of zero dose children in certain areas; and**
- insecurity in those areas that are the source of cVDPV transmission.

Contributing factors include:

- **Weak routine immunization:** Many countries have weak immunization systems that can be further impacted by humanitarian emergencies including conflict and protracted complex

emergencies. This poses a growing risk, leaving populations in these fragile states vulnerable to polio outbreaks.

- **Lack of access:** Inaccessibility continues to be a major risk, particularly in northern Yemen and Somalia which have sizable populations that have been unreached with polio vaccine for extended periods of more than a year...

...Additional considerations

The committee noted that the genetic diversity of WPV1 continues to shrink in the single epidemiological block of Afghanistan and Pakistan, and that case numbers of cVDPV1 and cVDPV2 continue to decrease globally, for example in Madagascar, which following intensive vaccine response appears to have halted transmission since September 2023. As demonstrated by environmental surveillance, international spread continues, emphasizing the need to further strengthen cross border collaboration in all areas of polio eradication such as surveillance and data sharing, not only in synchronization of case response immunization rounds and border vaccination posts.

The Committee recognizes the concerns regarding the lengthy duration of the polio PHEIC and the importance of exploring alternative measures. The committee noted the current review of the International Health Regulations taking place and that amendments to the Regulations were possible in 2024. The Committee felt it was still too early to discontinue the PHEIC as the risk of exportation of both WPV and cVDPVs remains significant and the removal of the PHEIC may send the wrong message at this critical juncture in polio eradication.

The committee appreciates the commitment of the Afghan authorities to the global goal of polio eradication, notes and appreciates the increased use of women health care workers in campaigns, and strongly encourages house to house campaigns be implemented wherever feasible as these campaigns enhance identification and coverage of zero dose and under-immunized children. The committee was concerned by the pause in testing and reporting of polio test results during January and February 2024 that has led to a large backlog of specimens and heightened the risk of undetected transmission and late detections of outbreaks. Given the historically very high standards achieved for surveillance sensitivity and timeliness of detection, avoiding any further recurrence is essential to ensure the timely identification and assessment of risk to inform continued effective vaccination response in Afghanistan. The committee urges all countries to ensure that polio detection and outbreak response is as timely as possible.

The committee noted that environmental surveillance had played a significant role in detection of the new outbreaks detected in several countries, such as Angola, Liberia and Sierra Leone and encouraged countries to continue to work to improve the quality of ES to maximize the benefits of its implementation.

The committee was concerned to hear about the ongoing supply issues regarding novel OPV2 and noted the plans to obtain a second supplier. The committee considered that the securing of vaccine supply was a critical issue, and that there should be planning to ensure a more robust vaccine supply beyond admission of a new supplier. While encouraging countries to declare public health emergencies following detection of a new outbreak, such crucial actions need to be supported by the GPEI in ensuring vaccine availability.

Many of the cVDPV infected countries remain conflict affected, disrupting routine immunization. Nevertheless, steps should be taken to increase coverage of the second dose of IPV, to prevent children from being crippled. Front line workers need to be protected from harm

during the course of their duties, as the interplay between insecurity, poor polio vaccine coverage, and risk of cVDPV is clear.

Based on the current situation regarding WPV1 and cVDPVs, and the reports provided by affected countries, the **Director-General accepted the Committee's assessment and on 28 March 2024 determined that the poliovirus situation continues to constitute a PHEIC with respect to WPV1 and cVDPV. The Director-General endorsed the Committee's recommendations** for countries meeting the definition for 'States infected with WPV1, cVDPV1 or cVDPV3 with potential risk for international spread', 'States infected with cVDPV2 with potential risk for international spread' and for 'States previously infected by WPV1 or cVDPV within the last 24 months' and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of poliovirus, effective 28 March 2024.

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

WHO & Regional Offices [to 12 Apr 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

12 April 2024 Departmental news

[Enhancing Global Health and Well-Being: WHO and the Netherlands strengthen their Partnership](#)

12 April 2024 News release

[In world first, Nigeria introduces new 5-in-1 vaccine against meningitis](#)

11 April 2024 Departmental news

[World Chagas Disease Day 2024: urging early diagnosis and care for life](#)

9 April 2024 News release

[WHO sounds alarm on viral hepatitis infections claiming 3500 lives each day](#)

9 April 2024 Departmental news

[WHO announces forthcoming updates on co-administration of treatment for drug-resistant tuberculosis and hepatitis C](#)

8 April 2024 Statement

[Statement following the Thirty-eighth Meeting of the IHR Emergency Committee for Polio](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: [**Malawi curbs cholera through enhanced outbreak control**](#) 11 April 2024

Lilongwe – Although Malawi continues to record only sporadic cholera cases, with just an average of 10 cases a week as of January 2024 compared with close to 700 cases per week at the peak of the outbreak in January 2023 – infection control measures are being applied rigorously to further curb the disease, save lives and avert a flare-out.

At the heart of the measures being undertaken is the 7-1-7 approach: essentially it entails timely case detection (a target of less than seven days from emergence of infection), notification (a target of less than a day from detection) and completion of seven early response actions (a target of below seven days from notification)...

WHO Region of the Americas PAHO

:: 11 Apr 2024

[**PAHO Director meets with Minister of Health of Canada to discuss ongoing collaboration with the country**](#)

Ottawa, Canada, 11 April 2024 (PAHO) – During an official visit to Canada this week, Pan American Health Organization (PAHO) Director, Dr. Jarbas Barbosa, met with the country's Minister of Health, Mark Holland, as well as other high-level health officials, to discuss ongoing collaboration to enhance quality of life and health in the Americas.At...

:: 10 Apr 2024

[**WHO sounds alarm on viral hepatitis infections claiming 3500 lives each day**](#)

Geneva, 10 April, 2024 — According to the World Health Organization (WHO) 2024 Global Hepatitis Report, the number of lives lost due to viral hepatitis is increasing. The disease is the second leading infectious cause of death globally -- with 1.3 million deaths per year, the same as tuberculosis, a top infectious killer.The report, released at...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

:: [**Visiting Lebanon, WHO Regional Director affirms support to address multiple health system challenges**](#) 7 April 2024

:: [**The right to health: WHO works to bridge health divide in Yemen**](#) 7 April 2024

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations.

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[10 April 2024 | Rabies - Timor-Leste](#)

[9 April 2024 | Avian Influenza A\(H5N1\) - United States of America](#)

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 15, pp. 179–184 **12 April 2024**

PDF: <https://iris.who.int/bitstream/handle/10665/376507/WER9915-eng-fre.pdf>

:: Strategic and Technical Advisory Group on Infectious Hazards with Pandemic and Epidemic Potential: annual meeting, "New vulnerabilities"

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

11 April 2024

[Target product profile for a low-cost test for use in bacterial meningitis outbreak response and surveillance](#)

11 April 2024

[Respiratory pathogens pandemic preparedness: perspectives on research priorities and key measures of...](#)

11 April 2024

[HRP annual report 2023](#)

9 April 2024

[Consolidated guidelines on person-centred viral hepatitis strategic information: using data to support...](#)

9 April 2024

[Global hepatitis report 2024: action for access in low- and middle-income countries](#)

9 April 2024

[Co-administration of treatment for drug-resistant tuberculosis and hepatitis C: rapid communication](#)

8 April 2024

[Diagnostic tests for detecting risk of Plasmodium vivax relapse](#)

.....

.....

USA – HHS, FDA, CDC

HHS

News

No new digest content identified.

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

[Vaccines and Related Biological Products Advisory Committee May 16, 2024 Meeting Announcement - 05/16/2024](#)

CDC/ACIP [U.S.] [to 12 Apr 2024]

<http://www.cdc.gov/media/index.html>

Latest News Releases

[CDC Data Modernization Efforts Accelerate Nation's Ability to Detect and Rapidly Respond to Health Threats](#)

April 11, 2024

CDC highlights progress from 2023 and sets ambitious goals for 2024-2025

Today the Centers for Disease Control and Prevention (CDC) launched its updated [Public Health Data Strategy for 2024-2025](#) and a companion [2023 Lookback Report](#). First launched in 2023, the strategy outlines the data, technology, policy, and administrative actions essential to address challenges in data exchange between healthcare organizations and public health authorities and between state, tribal, local, territorial and federal public health authorities. Seamless sharing of data helps ensure our nation can rapidly detect and respond to new threats.

The strategy advances the priorities of the [CDC's Data Modernization Initiative \(DMI\)](#) in concrete and measurable increments. The accomplishments of 2023 better positioned our nation to detect and respond in near real-time to health threats and inform the public by better connecting public health to healthcare data systems and advancing tools that streamline work...

ACIP Meetings

Next ACIP Meeting

June 26-28

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

April 11, 2024 / No. 14

[PDF of this issue](#)

- [Measles — United States, January 1, 2020–March 28, 2024](#)
- [COVID-19 Vaccination Coverage — World Health Organization African Region, 2021–2023](#)
- [Infections Associated with Medtronic Duet External Ventricular Drains — Rhode Island Hospital, Providence, Rhode Island, January 2023–January 2024](#)

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

No new digest content identified.

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en/News/Updates/Reports/Publications> [Selected]
News

[HIV service delivery in Europe and Central Asia severely disrupted during COVID-19 pandemic](#)

10 Apr 2024

Surveillance and monitoring

[Communicable disease threats report, 7 - 13 April 2024, week 15](#)

12 Apr 2024

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7 - 13 April 2024 and includes updates on measles, avian influenza, COVID-19, Mpox, seasonal influenza, RSV, cholera and shigellosis.

Surveillance and monitoring

[The impact of the COVID-19 pandemic on the HIV response in Europe and Central Asia - Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia](#)

10 Apr 2024

This report provides a record of the impact noted by countries on HIV services and monitoring capacity which can be used retrospectively to better understand the effects of the COVID-19 pandemic on the HIV situation in the European Region.

Assessment

[Interim analysis of COVID-19 vaccine effectiveness against hospitalisation due to COVID-19 and death using electronic health records in eight European countries: first update](#)

8 Apr 2024

This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥ 50 years of age living in the community.

.....

.....

Africa CDC [to 12 Apr 2024]

<https://africacdc.org/>

Press Releases, Statements [Selected]

No new digest content identified.

.....

.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 12 Apr 2024]

<http://en.nhc.gov.cn/>

[NHC vice-minister meets with Merieux Foundation president](#)

Updated: 2024-04-12

On April 9, Cao Xuetao, vice-minister of the National Health Commission (NHC), met with President of the Merieux Foundation Alain Merieux in Beijing.

National Medical Products Administration – PRC [to 12 Apr 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

Weekly Reports: Current Volume (6)

2024-04-12 / No. 15 COVID-19 ISSUE (40)

[PDF of this issue](#)

- [Preplanned Studies: A Large-Scale Online Survey on Clinical Severity and Associated Risk Factors for SARS-CoV-2 Omicron Infection — China, April–May 2023](#)
- [Preplanned Studies: Investigation of Nasal Mucosal IgA Responses in the Population Following COVID-19 Pandemic — China, September 2022–August 2023](#)
- **[Preplanned Studies: Predictors of Global Disparities in COVID-19 Vaccination Coverage — 219 Countries and Territories, December 2020–July 2022](#)**
- [Vital Surveillances: Genomic Surveillance for SARS-CoV-2 Variants: Dominance of XBB Replacement — China, January–June 2023](#)
- [Methods and Applications: Early Detection of the Emerging SARS-CoV-2 BA.2.86 Lineage Through Wastewater Surveillance Using a Mediator Probe PCR Assay — Shenzhen City, Guangdong Province, China, 2023](#)
- [HTML\(215\) PDF 458KB\(1\)](#)

⋮
⋮

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

⋮
⋮

Organization Announcements

Paul G. Allen Frontiers Group [to 12 Apr 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 12 Apr 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 12 Apr 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 12 Apr 2024]

<https://carb-x.org/>

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 12 Apr 2024]

<http://cepi.net/>

Latest News

No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 12 Apr 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 12 Apr 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 12 Apr 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 12 Apr 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 12 Apr 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 12 Apr 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 12 Apr 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

[A qualitative review of COVID-19 experiences in low- and middle-income countries](#)

Added April 13, 2024

What is this? In this systematic review, the authors searched for qualitative literature on community responses during the COVID-19 pandemic in low- and middle-income countries. They restricted their searches to articles published in English between December 2019 and August 2021. The authors included 26 studies from Bolivia (1), Burkina Faso (1), Ethiopia (1), Ghana (3), India (4), Indonesia (7), Nepal (1), Nigeria (3), Pakistan (2), Philippines (1), Sierra Leone (1), and Uganda (1).

What was found: Communities around the world reacted to the COVID-19 pandemic in diverse and complex ways. The spread of disease was facilitated by misinformation and fear of social rejection, which led to non-compliance with pandemic restrictions, resistance, and isolation. Perceptions of COVID-19 were influenced by traditional, religious, and biomedical epistemologies that occasionally conflicted. Communities adapted to traditional and biomedical practices that demonstrated resilience and offered models to improve public health outcomes.

Fondation Merieux [to 12 Apr 2024]

<http://www.fondation-merieux.org/>

News, Events

Projet

[Clôture du projet APRECIT : Une avancée dans la lutte contre la tuberculose à Madagascar et au Cameroun](#)

4 avril 2024 - Cameroun et Madagascar

Quatre ans après son lancement, le Projet d'Amélioration de la Prise en Charge de l'Infection Tuberculeuse (APRECIT) à Madagascar et au Cameroun touche à sa fin. La cérémonie de clôture est célébrée au Centre Pasteur Cameroun (CPC) fin janvier, puis à l'Institut Pasteur de Madagascar le 26 mars. Lancé en 2020, ce projet a été piloté par la Fondation Mérieux en collaboration étroite avec les Programmes Nationaux de Lutte contre la Tuberculose (PNLT) des deux pays, le Centre Pasteur du Cameroun, et l'Institut Pasteur de Madagascar.

Gavi [to 12 Apr 2024]

<https://www.gavi.org/>

Press Releases

[Brazilian Ministry of Health and Gavi reaffirm partnership to advance equitable immunisation globally](#)

Geneva/Brasilia, 11 April 2024 – The Brazilian Ministry of Health (MoH) and Gavi, the Vaccine Alliance have signed a landmark Memorandum of Understanding (MoU) to collaborate on vaccine production, innovation and global access. This strengthened partnership reaffirms both partners' commitment to ensuring equitable access to life-saving vaccines. Gavi and Brazil will also promote integrating global health with other critical areas like finance, climate change and digital technology as part of the MoU...

GE2P2 Global Foundation [to 12 Apr 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – March 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 07 March 2024 – Issue 14](#)

GHIT Fund [to 12 Apr 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 12 Apr 2024].

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 12 Apr 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 12 Apr 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 12 Apr 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 12 Apr 2024]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IIVI [to 12 Apr 2024]

<https://www.iavi.org/>

News, Features

No new digest content identified.

INSERM [to 12 Apr 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

12 April 2024

[ICMRA Summit 2023 Melbourne Meeting Report](#)

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 12 Apr 2024]

<https://www.ich.org/page/press-releases>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 12 Apr 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

[Joint press release: International Red Cross and Red Crescent Movement urges support for conflict victims: "We cannot let Sudan become another forgotten crisis"](#)

__Port Sudan/Nairobi/Geneva - One year of conflict in Sudan is taking a devastating human toll.

Over 8 million people have been displaced, and tens of thousands have been killed or wounded.

08-04-2024 | News release

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 12 Apr 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

Press release 10/04/2024

[IFRC calls for humane implementation of the European Pact on Asylum and Migration](#)

Press release 08/04/2024

International Red Cross and Red Crescent Movement urges support for conflict victims: 'We cannot let Sudan become another forgotten crisis'

Press release 07/04/2024

Gaza: Six months of inhumanity

Institut Pasteur [to 12 Apr 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 12 Apr 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 12 Apr 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 12 Apr 2024]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 12 Apr 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

Leaders in biosecurity commend NSCEB Interim Report and AIxBio policy options paper, make additional recommendations

April 9, 2024 – The Johns Hopkins Center for Health Security (CHS), Federation of American Scientists (FAS), Nuclear Threat Initiative Global Biological Policy and Programs (NTI|bio), and Scowcroft Institute of International Affairs at the Bush School of Government and Public Service provided comments to the National Security Commission on Emerging Biotechnology (NSCEB) on its recent Interim Report and White Paper on Policy Options for Artificial Intelligence and Biotechnology (AIxBio)

Collectively, these organizations represent some of the major civil society organizations with expertise in biosecurity that are developing policies around the governance of AIxBio. NSCEB was tasked with reviewing how advancements in emerging biotechnology and related technologies will shape current and future national defense activities. The NSCEB's Interim Report was submitted in December 2023. The final report will include policy recommendations that respond to its mandate and is due to Congress in December 2024.

The response letter presents a detailed outline offering targeted recommendations and select responses to:

- Prioritize the mitigation of high-consequence biological risks that could be generated by AI model capabilities.
- Strengthen AIxBio policy options to ensure responsible and trustworthy biotechnology innovation.
- Add considerations for NSCEB to adopt for its final report that would help fully harness the benefits of AIxBio technologies while improving their safety and security...

MSF/Médecins Sans Frontières [to 12 Apr 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

Conflict in Sudan

[After a year of war in Sudan, a rapid scale up of response is needed to avoid catastrophe](#)

12 Apr 2024

Haiti

[In Port-au-Prince, the "violence is like gangrene, spreading and threatening us all."](#)

10 Apr 2024

Conflict in Sudan

[In Sudan, "the needs are growing by the day, but the response is deeply inadequate"](#)

8 Apr 2024

National Academy of Medicine - USA [to 12 Apr 2024]

<https://nam.edu/programs/>

News [Selected]

[New Paper Outlines Draft Code of Conduct to Ensure That the Use of AI In Health and Health Care Meets Its Full Potential Reliably and Safely](#)

April 8, 2024

"This moment presents a unique opportunity for the health care community ... to act collectively and with intention to design the future in the era of AI."

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 12 Apr 2024]

<https://www.nationalacademies.org/newsroom?>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 12 Apr 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

June 13-14, 2024

NIH [to 12 Apr 2024]

<http://www.nih.gov/>

New Releases

No new digest content identified.

PATH [to 12 Apr 2024]

<https://www.path.org/media-center/>

Newsroom

No new digest content identified.

Sabin Vaccine Institute [to 12 Apr 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 12 Apr 2024]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

Press statement

[Monaco Principality renews its collaboration with UNAIDS](#)

GENEVA/MONACO, 11 April 2024

UNICEF [to 12 Apr 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

No new digest content identified.

Unitaid [to 12 Apr 2024]

<https://unitaid.org/>

Featured News

12 April 2024

[Ahead of World Chagas Day, Unitaid reiterates its commitment to fighting Chagas disease](#)

Vaccine Equity Cooperative [nee Initiative] [to 12 Apr 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 12 Apr 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

Vaccination Acceptance Research Network

[VARN2023 Conference Report](#) [French]

April 2, 2024

Vaccine Confidence Project [to 12 Apr 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 12 Apr 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 12 Apr 2024]

<https://wellcome.org/>

News, Opinion, Reports

No new digest content identified.

The Wistar Institute [to 12 Apr 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

April 10, 2024

[Wistar Scientists Identify Pro-aging ‘Sugar Signature’ in the Blood of People Living with HIV](#)

PRESS RELEASE CONTACT: Darien Sutton 215-898-3988 | dsutton@wistar.org The Abdel-Mohsen lab findings shed light on how sugar molecules in the blood of people living with HIV may accelerate biolog...

World Bank [to 12 Apr 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 12 Apr 2024]

<https://www.wfpha.org/>

Event

[Global Public Health Week](#)

8-12 April 2024

[World Medical Association \[WMA\]](#) [to 12 Apr 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [to 12 Apr 2024]

<https://www.oie.int/en/>

Press Releases, Statements

No new digest content identified.

.....

.....

ARM [Alliance for Regenerative Medicine] [to 12 Apr 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 12 Apr 2024]

<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 12 Apr 2024]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 12 Apr 2024]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 12 Apr 2024]

<https://ifpma.org/>

News

Statement 9 Apr 2024

[Open letter from the biopharmaceutical industry to G20 Ministers in support of the advancement of the G20 Health Agenda](#)

On 9 April 2024, IFPMA, Interfarma, and FIFARMA submitted an open letter to G20 Ministers in support of the advancement of the G20 Health Agenda.

International Alliance of Patients' Organizations – IAPO [to 12 Apr 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 12 Apr 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - *No new digest announcements identified.*

Bharat Biotech

Press Releases - *No new digest announcements identified.*

BioCubaFarma – Cuba

Últimas Noticias - *No new digest announcements identified*

Biological E

News - *No new digest announcements identified.*

BioNTech

Press Releases -

7 April 2024

[Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer](#)

Boehringer

Press Releases

[Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets](#)

Boehringer Ingelheim Biopharmaceuticals China (BioChina), in collaboration with a customer, has successfully passed pre-approval inspections by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Ingelheim, Germany and Shanghai, China, Tue, 04/09/2024

As a result, the customer is now approved for the supply of the biopharmaceutical to the EU and US markets from product manufactured by Boehringer Ingelheim Biopharmaceuticals China. The inspections validated compliance with ICH, GxP regulations, international manufacturing standards, and patient safety requirements at Boehringer Ingelheim's OASIS manufacturing site in Shanghai. As part of the Boehringer Ingelheim Biopharmaceutical's global manufacturing network, BioChina continues to uphold the corporate values and commitment to providing safe, effective, and high-quality medications. "For us as a world-leading contract manufacturer of biopharmaceuticals, the official approvals for our site are a confirmation of our own aspiration to transform lives for generations," explains Ulrike Falk, Head of Global Quality Biopharma Operations at Boehringer Ingelheim...

CanSinoBIO

News - *Website not responding at inquiry*

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News

Apr 8, 2024

Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort

- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralization titers to approximately 6,600 IU/mL (6.4-fold increase) and approximately 46,000 IU/mL (12-fold increase), respectively --
-- Preliminary Phase I data in target older adult population is on track for H2-2024 --

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

GSK

Press releases for media - No new digest announcements identified

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified.

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease

April 09, 2024

- ABRYSCO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk. The vaccine was well-tolerated and demonstrated an immune response non-inferior to adults aged 60 years and older
- Pfizer intends to submit these findings to regulatory agencies to seek approval of ABRYSCO in adults 18 to 59 years of age

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS

April 12, 2024

[Serum Institute of India Collaborates with Univercells to bring Affordable Personalized Oncology to Masses](#)

Brussels, Belgium and Pune, India

In a landmark collaboration announced today, Serum Institute of India (SII), the world's largest vaccine manufacturer, has joined forces with Univercells, a Belgian biotech innovator, targeting a dramatic increase in accessibility to personalised cancer care. This partnership aims to bring cutting edge treatment options within reach of millions globally.

At present, personalised care options such as novel cancer vaccines and specialised immunotherapies are accessible to a few patients only. These new therapies are developed using genetic material extracted from the patient's tumours, a process which is both time-consuming, and expensive. Besides, due to strict regulatory limitations on the sequence, transfer, and manufacturing of genetic material, these treatments are only available in a handful of countries. This collaboration between SII and Univercells will help in addressing these challenges, with a view to capture a proportion of the global cancer care market.

The collaboration between Univercells and SII will tackle all three problems with a view to capturing a proportion of the global cancer care market...

Sinopharm/WIBPBIBP

News - No new digest announcements identified [English translation function not operating]

Sinovac

Press Releases

2024/04/12

[China National Medical Products Administration Granted Approval to SINOVAC's 5-dose Inactivated Poliomyelitis Vaccine](#)

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 4: E275-359 April 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

Global Medical Supply Chain Security

Individual patients' safety and public health were compromised by critical drug shortages, substandard medications, and extremely restricted access to personal protective equipment during the COVID-19 pandemic. As health organizations and workers struggled to meet demands posed by unprecedented patient numbers and illness acuity, our complex global health ecosystem with long-standing upstream supply chain vulnerabilities failed to meet emergent downstream demand in several ways. First, material procurement and ingredient sourcing were inadequate. Second, operations lacking transparency made stopping propagation of substandard or falsified medications ineffective, inefficient, or impossible. Finally, logistical obfuscation made environmental

consequences of waste management hard to assess and steward responsibly. Policy makers, health care organizations, regulators, manufacturers, and distributors each have roles in building and maintaining global medical supply chain security. This theme issue investigates how these and other agents' failures to cultivate public health capacity, nourish sustainable production processes, and carefully maintain systemic supply chain resiliency are neither accidental nor simply unfortunate, but unjust.

Case and Commentary Apr 2024

[Which Drugs Should Be on the Essential Medicines List?](#)

Courtney Perlino, MPP, Hilary Daniel, and Amy B. Cadwallader, PhD

The WHO has a list of essential medicines. What about medicines that might not get to patients who need them on time?

AMA Code Says Apr 2024

[AMA Code of Medical Ethics' Opinions Related to Global Medical Supply Chain Security](#)

Maura McGinnity

When global medical supply chains fail, what should physicians do?

AMA J Ethics. 2024;26(4):E303-305. doi: 10.1001/amajethics.2024.303.

State of the Art and Science Apr 2024

[Which Data Analytics Tool Should We Use to Evaluate Risk in Upstream Drug Supply Chains?](#)

Matt Christian, MSc and Wejdan Bagais, MSc

Drug shortages are persistent and serious in the US, affecting care quality and costs. An early warning system could help.

Medicine and Society Apr 2024

[How Should Critical Medications Be Rationed During Shortages?](#)

Erin R. Fox, PharmD, MHA and Matthew K. Wynia, MD, MPH

Recent increases in the frequency of shortages require more rationing by clinicians.

American Journal of Human Genetics

Apr 04, 2024 Volume 111 Issue 4 p621-806

<https://www.cell.com/ajhg/current>

[Reviewed earlier]

American Journal of Infection Control

April 2024 Volume 52 Issue 4p 381-499

<http://www.ajicjournal.org/current>

[New issue; No digest content identified]

American Journal of Preventive Medicine

April 2024 Volume 66 Issue 4p 573-750

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

American Journal of Public Health

May 2024 114(5)

<http://ajph.aphapublications.org/toc/ajph/current>

[New issue; No digest content identified]

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 4 (Apr 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/4/tpmd.110.issue-4.xml>

Perspectives

[Previous Malaria Exposures and Immune Dysregulation: Developing Strategies To Improve Malaria Vaccine Efficacy in Young Children](#)

Katherine R. Dobbs, et al.

Article Category: Perspective

DOI: <https://doi.org/10.4269/ajtmh.23-0696>

Page(s): 627–630

[Contemplating the Human Papillomavirus \(HPV\) Vaccine Introduction in Pakistan: Is Now the Time?](#)

[Rabab Batool](#)

Article Category: Perspective

DOI: <https://doi.org/10.4269/ajtmh.23-0790>

Page(s): 631–632

Annals of Internal Medicine

March 2024 Volume 177, Issue 3

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 330 May 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/330/suppl/C>

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 12 Apr 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 12 Apr 2024)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 12 Apr 2024)

[Willingness to receive COVID-19 vaccines, associated factors and reasons for not taking a vaccine: a cross sectional study among persons aged 13–80 years in Wakiso, Central Uganda](#)

Vaccination has been recommended as one of the approaches for the control of COVID-19 pandemic. However, adequate vaccine coverage is critical to the effectiveness of the vaccine at population level. Data on a...

Authors: Alex Daama, Naziru Rashid, Kasango Asani, Grace Kigozi Nalwoga, Fred Nalugoda, Robert Bulamba, Emmanuel Kyasanku, Gertrude Nakigozi, Godfrey Kigozi, Joseph Kagaayi and Stephen Mugamba

Citation: BMC Infectious Diseases 2024 24:391

Content type: Research Published on: 11 April 2024

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmethics/content>

(Accessed 12 Apr 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmmed/content>

(Accessed 12 Apr 2024)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 12 Apr 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 12 Apr 2024)

[Implementation of COVID-19 vaccination services in prison in six European countries: translating emergency intervention into routine life-course vaccination](#)

Evidence has shown that the risk of transmission of SARS-CoV-2 is much higher in prisons than in the community. The release of the COVID-19 vaccine and the recommendation by WHO to include prisons among priori...

Authors: Sara Mazzilli, Nicola Cocco, Davide Petri, Babak Moazen, Alicia Rosello, Jemima D'Arcy, Emma Plugge, Laura Baglietto, Eva Muraier, Heino Stöver, Tassos Trattonikolas, Iakovos Stylianou, Svetlana Doltu, Vladislav Busmachi, Josefina Mavrou, Ioanna Yiasemi...

Citation: BMC Public Health 2024 24:1001

Content type: Research Published on: 10 April 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 12 Apr 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

April 2024 - Volume 29 - 2

<https://ebm.bmj.com/content/29/2>

[Reviewed earlier]

BMJ Global Health

March 2024 - Volume 9 - 3

<https://gh.bmj.com/content/9/3>

[Reviewed earlier]

Bulletin of the Atomic Scientists

March 2024

<https://thebulletin.org/magazine/2024-03/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(4); 2024 Apr 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/458786/>

[Reviewed earlier]

Cell

Mar 28, 2024 Volume 187 Issue 7 p1567-1818

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 50, Issue 3 May 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[New issue; No digest content identified]

Clinical Pharmacology & Therapeutics

Volume 115, Issue 3 Pages: 375-626 March 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Subcutaneous Biologics: Clinical Pharmacology and Drug Development

[Reviewed earlier]

Clinical Therapeutics

March 2024 Volume 46 Issue 3 p185-304

<http://www.clinicaltherapeutics.com/current>

Editorial

[Adapting and Advancing the Criteria for Scientific Evidence, Marketing, and Advice in the Changing World](#)

Jill L. Maron

Published online: March 18, 2024

Clinical Trials

Volume 21 Issue 2, April 2024

<https://journals.sagepub.com/toc/ctja/21/2>

[New issue; No digest content identified]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 12 Apr 2024]

[The impact of conflict on infectious disease: a systematic literature review](#)

Conflict situations, armed or not, have been associated with emergence and transmission of infectious diseases. This review aims to identify the pathways through which infectious diseases emerge within conflict...

Authors: Valia Marou, Constantine I. Vardavas, Katerina Aslanoglou, Katerina Nikitara, Zinovia Plyta, Jo Leonardi-Bee, Kirsty Atkins, Orla Condell, Favelle Lamb and Jonathan E. Suk

Citation: Conflict and Health 2024 18:27

Content type: Review Published on: 8 April 2024

Contemporary Clinical Trials

Volume 138 March 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/1387/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 1 / February 2024

<https://www.liebertpub.com/toc/crispr/7/1>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 3 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

April 2024 - Volume 37 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 12 Apr 2024]
[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 1 Pages: 1-48 March 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

Access to Essential Medicines for Global Health and the Human Right to Health

[Reviewed earlier]

Development in Practice

Volume 34, Issue 2, 2024

<https://www.tandfonline.com/toc/cdip20/34/2>

Article

[Economic recovery of the new poor created by COVID-19: evidence from Bangladesh](#)

Mohima Gomes, Nusrat Jahan, Tanvir Shatil, Nabila Tahsin, Narayan Das & Imran Matin

Pages: 221-237

Published online: 06 Nov 2023

Development Policy Review

Volume 42, Issue 2 March 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 48, Issue 2 April 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/2>

[Reviewed earlier]

EMBO Reports

Volume 25 Issue 4 12 April 2024

<https://www.embopress.org/toc/14693178/current>

Editorial 20 March 2024

[AI to publish knowledge: a tectonic shift](#)

Thomas Lemberger

The rise of generative AI will transform scientific publishing but it also poses risks. While AI enables the dissemination of knowledge in computable form, preserving transparency and human values will become even more important for maintaining trust in the scientific discourse.

Opinion 5 February 2024

[Clinical trials and tribulations](#)

Frank Gannon

We need better post-approval monitoring and reporting to assess the efficiency of new cancer therapies in the real world beyond clinical trials.

Science & Society 4 March 2024

[The ethical and legal challenges of human foetal brain tissue-derived organoids: At the intersection of science, ethics, and regulation](#)

Tsutomu Sawai, Masanori Kataoka

The recent generation of brain organoids from human foetal tissue highlights the need for nuanced ethical considerations and international coordination to navigate the complexities of this research and its broader implications for developmental neuroscience and ethical debates.

Emerging Infectious Diseases

Volume 30, Number 4—April 2024

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 46 March 2024

<https://www.sciencedirect.com/journal/epidemics/vol/46/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 2 Pages: 1-35 March–April 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Indigenous data sovereignty :: Returning clinically relevant results

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 2, April 2024

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

March/April 2024 Volume 103, Number 2

<https://www.foreignaffairs.com/issues/2023/103/2>

[Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 4 April 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/4>

[New issue; No digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 12 Apr 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 1 February 28, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 12 Apr 2024]

Book/Printed Material

[Legal treatment of embryos created through IVF : Australia, France, Germany, Italy, New Zealand, Poland, Portugal, Sweden, United Kingdom](#) "LL File No. 2024-023075." "March 2024." Includes bibliographical references. Description based on online resource; title from PDF cover (Law Library of Congress, viewed March 5, 2024).

Contributor: Gilbert, Louis A. - Hofverberg, Elin - Feikert-Ahalt, Clare - Gesley, Jenny - Law Library of Congress (U.S.). Global Legal Research Directorate - Fremer, Iana - Buchanan, Kelly (Kelly S.) - Figueroa, Dante - Soares, Eduardo (Eduardo Da Gama)
Date: 2024

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 12 Apr 2024]

[No new digest content identified]

Health and Human Rights

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

Special Section: Economic Inequality and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 1 - January 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 3, April 2024

<https://academic.oup.com/heapol/issue/39/3>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 12 Apr 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 5-6 / March 2024

<https://www.liebertpub.com/toc/hum/35/5-6>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

Immunity

Mar 12, 2024 Volume 57 Issue 3 p401-612

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 12 Apr 2024]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 12 Apr 2024]

[Towards an actionable One Health approach](#)

Authors: Xiao-Xi Zhang, Zohar Lederman, Le-Fei Han, Janna M. Schurer, Li-Hua Xiao, Zhi-Bing Zhang, Qiu-Lan Chen, Dirk Pfeiffer, Michael P. Ward, Banchob Sripana, Sarah Gabriël, Kuldeep Dhama, Krishna Prasad Acharya, Lucy J. Robertson, Sharon L. Deem, Cécile Aenishaenslin...

Content type: Opinion 12 April 2024

Despite the increasing focus on strengthening One Health capacity building on global level, challenges remain in devising and implementing real-world interventions particularly in the Asia-Pacific region. Recognizing these gaps, the One Health Action Commission (OHAC) was established as an academic community for One Health action with an emphasis on research agenda setting to identify actions for highest impact.

International Health

Volume 16, Issue 2, March 2024

<https://academic.oup.com/inthealth/issue/16/2>

[Reviewed earlier]

International Human Rights Law Review

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 3 (2024): March 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/110>

[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 2, April 2024

<https://academic.oup.com/ije/issue/53/2>

Opinion

[**Moral jeopardy, conflicts of interest and the integrity of public health research**](#)

Peter J Adams and Melissa-Jade Gregan

International Journal of Human Rights in Healthcare

Volume 17 Issue 1 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1>

Table of contents

[Reviewed earlier]

JAMA

April 9, 2024, Vol 331, No. 14, Pages 1165-1254

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Health Forum

April 2024, Vol 5, No. 4

<https://jamanetwork.com/journals/jama-health-forum/issue>

[New issue; No digest content identified]

JAMA Pediatrics

April 2024, Vol 178, No. 4, Pages 326-422

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

JBI Evidence Synthesis

March 2024 - Volume 22 - Issue 3

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

April 2024 Volume 74 Issue 4 p629-860

<https://www.jahonline.org/current>

Editorial

[**Syncope and Vaccinations: A Needed Step Forward**](#)

Emily A. Fisher

Published in issue: April 2024
p632-633

Journal of Artificial Intelligence Research

Vol. 79 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 2 April 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-2>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

Journal of Development Economics

Volume 168 May 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/168/suppl/C>

[New issue; No digest content identified]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 1-2, February–April 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

March 2024 - Volume 78 - 3

<https://jech.bmj.com/content/78/3>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 1 Pages: 1-235 March 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[New issue; No digest content identified]

Journal of Global Ethics

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 1, February 2024

<https://muse.jhu.edu/issue/52063>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 2 April 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-2>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 229, Issue 3, 15 March 2024

<https://academic.oup.com/jid/issue/229/3>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 3 Pages: 3-1943 April 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[New issue; No digest content identified]

Journal of Medical Ethics

April 2024 - Volume 50 - 4

<http://jme.bmj.com/content/current>

Original research

[**Blaming the unvaccinated during the COVID-19 pandemic: the roles of political ideology and risk perceptions in the USA**](#) (9 June, 2023)

Maja Graso, Karl Aquino, Fan Xuan Chen, Kevin Bardosh

[**Enhancing social value considerations in prioritising publicly funded biomedical research: the vital role of peer review**](#) (24 May, 2023)

Katherine W Saylor, Steven Joffe

[**The ethics of firing unvaccinated employees**](#) (30 May, 2023)

Maxwell J Smith

Extended essay

[Research ethics and public trust in vaccines: the case of COVID-19 challenge trials](#) (20

May, 2022)

Nir Eyal

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 1 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

Editorial

[Research Frameworks: Critical Components for Reporting Qualitative Health Care Research](#)

Ann Z. George

Reviews

[Patient Perspectives on the Use of Artificial Intelligence in Health Care: A Scoping Review](#)

Sally Moy, Mona Irannejad, Stephanie Jeanneret Manning, Mehrdad Farahani, Yomna Ahmed, Ellis Gao, Radhika Prabhune, Suzan Lorenz, Raza Mirza, and Christopher Klinger

Artificial intelligence (AI) technology is being rapidly adopted into many different branches of medicine. Although research has started to highlight the impact of AI on health care, the focus on patient perspectives of AI is scarce. This scoping review aimed to explore the literature on adult patients' perspectives on the use of an array of AI technologies in the health care setting for design and deployment.

The Journal of Pediatrics

Volume 266 March 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/266/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

March/April 2024 - Volume 30 - Issue 2

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 1, March 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-1>

[Reviewed earlier]

Journal of the Royal Society – Interface

April 2024 Volume 21 Issue 213

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

Journal of Travel Medicine

Volume 31, Issue 3 April 2024

<https://academic.oup.com/jtm/issue>

Review

[Humoral immunogenicity of primary yellow fever vaccination in infants and children: a systematic review, meta-analysis and meta-regression](#)

Pietro Ferrara and others

[Piloting delivery of PfSPZ vaccines for malaria through a cryogenic vaccine cold chain to travel and military medicine clinics](#)

Eric R. James and others

Journal of Virology

Volume 98 • Number 2 • February 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Apr 13, 2024 Volume 403 Number 10435 p1419-1512

<https://www.thelancet.com/journals/lancet/issue/current>

Health Policy

[A legal mapping of 48 WHO member states' inclusion of public health emergency of international concern, pandemic, and health emergency terminology within national emergency legislation in responding to health emergencies](#)

Clare Wenham, Liam Stout

Open Access

Summary

WHO has determined a public health emergency of international concern (PHEIC) seven times, and beyond this nomenclature declared COVID-19 to be a pandemic. Under the International Health Regulations (IHR), and through their operationalisation in the joint external evaluation (JEE), governments are urged to create suitable legislation to be able to enact a response to a public health emergency. Whether the pandemic declaration had a greater effect than a PHEIC in encouraging governments to act, however, remains conjecture, as there is no systemic analysis of what each term means in practice and whether either has meaningful legal implications at the national level.

We undertook a legal scoping review to assess the utilisation of PHEIC and pandemic language within national legislation in 28 WHO member states. Data were collected from national websites, JEE reviews, COVID Analysis and Mapping of Policies Tool, Natlex, and Oxford Compendium of National Legal Responses to COVID-19. We found that only 16% of countries have any reference to the PHEIC in national legislation and 37.5% of countries reference the term pandemic.

This finding paints a weakened picture of the IHR and PHEIC mechanisms. Having such legalese enshrined in legislation might enhance the interaction between WHO determining a PHEIC or declaring a pandemic and resulting action to mitigate transnational spread of disease and enhance health security. Given the ongoing negotiations at WHO in relation to the amendments to the IHR and creation of the pandemic accord, both of which deal with this declaratory power of the PHEIC and pandemic language, negotiators should understand the possible implications of any changes to these proclamations at the national level and for global health security.

The Lancet Child & Adolescent Health

Mar 2024 Volume 8 Number 3 p175-244, e2-e5
<https://www.thelancet.com/journals/lanchi/issue/current>
[Reviewed earlier]

Lancet Digital Health

Mar 2024 Volume 6 Number 3 e145-e229
<https://www.thelancet.com/journals/landig/issue/current>
[Reviewed earlier]

Lancet Global Health

Mar 2024 Volume 12 Number 3 e341-e529
<https://www.thelancet.com/journals/langlo/issue/current>
[Reviewed earlier]

Lancet Infectious Diseases

Mar 2024 Volume 24 Number 3 p217-328, e137-e206
<https://www.thelancet.com/journals/laninf/issue/current>
[Reviewed earlier]

Lancet Public Health

Mar 2024 Volume 9 Number 3 e147-e206
<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

Mar 2024 Volume 12 Number 3 p181-254, e7-e12
<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 3 March 2024
<https://link.springer.com/journal/10995/volumes-and-issues/28-3>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 3, April 2024
<http://mdm.sagepub.com/content/current>
[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 1 Pages: 1-269 March 2024
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Mar 06, 2024 Volume 32 Issue 3 p563-856
<https://www.cell.com/molecular-therapy/current>
[Reviewed earlier]

Nature

Volume 628 Issue 8007, 11 April 2024
<https://www.nature.com/nature/volumes/627/issues/8007>
Opinion

[AI can help to tailor drugs for Africa — but Africans should lead the way](#)

Computational models that require very little data could transform biomedical and drug development research in Africa, as long as infrastructure, trained staff and secure databases are available.

Gemma Turon, Mathew Njoroge, Kelly Chibale

Nature Biotechnology

Volume 42 Issue 3, March 2024
<https://www.nature.com/nbt/volumes/42/issues/3>
[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>
(Accessed 12 Apr 2024)
[No new digest content identified]

Nature Genetics

Volume 56 Issue 3, March 2024
<https://www.nature.com/ng/volumes/56/issues/3>
[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 3, March 2024
<https://www.nature.com/nathumbehav/volumes/8/issues/3>
[Reviewed earlier]

Nature Medicine

Volume 30 Issue 3, March 2024
<https://www.nature.com/nm/volumes/30/issues/3>
[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 3, March 2024

<https://www.nature.com/nrd/volumes/23/issues/3>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 3, March 2024

<https://www.nature.com/nrg/volumes/25/issues/3>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 3, March 2024

<https://www.nature.com/nri/volumes/24/issues/3>

[Reviewed earlier]

New England Journal of Medicine

Volume 390 No. 13 April 04, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

Editorials

[Treating Acute Covid-19 — Final Chapters Still Unwritten](#)

R.T. Gandhi and M. Hirsch

NEJM Evidence

Volume 3 No. 4 April 2024

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 12 Apr 2024]

[No new digest content identified]

Pediatrics

Volume 153, Issue 4 April 2024

<https://publications.aap.org/pediatrics/issue/153/4>

[Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 3 March 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-3>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 12 Apr 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 12 Apr 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 12 Apr 2024)

[The World Health Organization was born as a normative agency: Seventy-five years of global health law under WHO governance](#)

Lawrence O. Gostin, Benjamin Mason Meier, Safura Abdool Karim, Judith Bueno de Mesquita, Gian Luca Burci, Danwood Chirwa, Alexandra Finch, Eric A. Friedman, Roojin Habibi, Sam Halabi, Tsung-Ling Lee, Brigit Toebes, Pedro Villarreal

Review | published 11 Apr 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002928>

Abstract

The World Health Organization (WHO) was born as a normative agency and has looked to global health law to structure collective action to realize global health with justice. Framed by its constitutional authority to act as the directing and coordinating authority on international health, WHO has long been seen as the central actor in the development and implementation of global health law. However, WHO has faced challenges in advancing law to prevent disease and promote health over the past 75 years, with global health law constrained by new health actors, shifting normative frameworks, and soft law diplomacy. These challenges were exacerbated amid the COVID-19 pandemic, as states neglected international legal commitments in national health responses. Yet, global health law reforms are now underway to strengthen WHO governance, signaling a return to lawmaking for global health. Looking back on WHO's 75th anniversary, this article examines the central importance of global health law under WHO governance, reviewing the past successes, missed opportunities, and future hopes for WHO. For WHO to meet its constitutional authority to become the normative agency it was born to be, we offer five proposals to reestablish a WHO fit for purpose: normative instruments, equity and human rights mainstreaming, sustainable financing, One Health, and good governance. Drawing from past struggles, these reforms will require further efforts to revitalize hard law authorities in global health, strengthen WHO leadership across the global governance landscape, uphold equity and rights at the center of global health law, and expand negotiations in global health diplomacy.

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 12 Apr 2024)

[Long-term variations of urban–Rural disparities in infectious disease burden of over 8.44 million children, adolescents, and youth in China from 2013 to 2021: An observational study](#)

Li Chen, Yi Xing, Yi Zhang, Junqing Xie, Binbin Su, Jianuo Jiang, Mengjie Geng, Xiang Ren, Tongjun Guo, Wen Yuan, Qi Ma, Manman Chen, Mengjie Cui, Jieyu Liu, Yi Song, Liping Wang, Yanhui Dong, Jun Ma

Research Article | published 12 Apr 2024 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004374>

... *Conclusions*

A significant urban–rural disparity in notifiable infectious diseases among children, adolescents, and youths was evident from our study. The burden in urban areas exceeded that in rural areas by more than 2-fold, and this gap appears to be widening, particularly influenced by tuberculosis, scarlet fever, infectious diarrhea, and typhus. These findings underscore the urgent need for interventions to mitigate infectious diseases and address the growing urban–rural disparity.

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 12 Apr 2024)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 12 Apr 2024]

[**Who shares fake news on social media? Evidence from vaccines and infertility claims in sub-Saharan Africa**](#)

Kerstin Unfried, Jan Priebe

Research Article | published 09 Apr 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0301818>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 12 Apr 2024]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

April 9, 2024 vol. 121 no. 15

<https://www.pnas.org/toc/pnas/121/15>

Research Article April 1, 2024

[**Spatial spillovers of violent conflict amplify the impacts of climate variability on malaria risk in sub-Saharan Africa**](#)

Africa carries a disproportionately high share of the global malaria burden, accounting for 94% of malaria cases and deaths worldwide in 2019. It is also a politically unstable region and the most vulnerable continent to climate change in recent decades. ...

Qiwei Yu, Ying Qu, [...] Suhong Liu

PNAS Nexus

Volume 3, Issue 3, March 2024

<https://academic.oup.com/pnasnexus/issue/3/3>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 1 - February 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 180 March 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/180/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

10 April 2024 Volume 291 Issue 2020

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 228 Pages e1-e4, 1-206 (March 2024)

<https://www.sciencedirect.com/journal/public-health/vol/228/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 16, Issue 3, November 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 2, March/April 2024

<https://journals.sagepub.com/toc/phrg/139/2>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 5, April 2024

<https://journals.sagepub.com/toc/QHR/current>

[New issue; No digest content identified]

Research Ethics

Volume 20 Issue 2, April 2024

<http://journals.sagepub.com/toc/reab/current>

Special collection: Research Integrity and Research Misconduct

Original Articles

Research article First published January 19, 2024

['A commitment to Equality, Diversity and Inclusion': a conceptual framework for equality of opportunity in Patient and Public Involvement in research](#)

Sapfo Lignou, et al.

Research article First published October 11, 2023

[Ethical human participant research in Central Asia: a quantitative analysis of attitudes and practices among social science researchers based in the region](#)

Aipara Berekeyeva, et al.

Research article First published October 31, 2023

[Challenges facing Arab researchers in conducting and publishing scientific research: a qualitative interview study](#)

Alya Elgamri, et al.

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 12 Apr 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

[No new digest content identified]

Risk Analysis

Volume 44, Issue 3 Pages: 509-737 March 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 12 Apr 2024]

[Reviewed earlier]

Science

Volume 384| Issue 6692|12 Apr 2024

<https://www.science.org/toc/science/current>

Editorial

[Teach philosophy of science](#)

BY H. Holden Thorp

11 Apr 2024:

Much is being made about the erosion of public trust in science. Surveys show a modest decline in the United States from a very high level of trust, but that is seen for other institutions as well. What is apparent from the surveys is that a better explanation of the nature of science—that it is revised

as new data surface—would have a strong positive effect on public trust. Because scientists are so aware of this feature, it is often taken for granted that the public understands this too. A step toward addressing this problem would be revising undergraduate and graduate curricula to teach not just theories and techniques but the underlying philosophy of science as well...

Science and Engineering Ethics

Volume 30, Issue 2 April 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-2>

[Reviewed earlier]

Science Translational Medicine

Volume 16|Issue 742| 10 Apr 202

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 12 Apr 2024]

[No new digest content identified]

Social Science & Medicine

Volume 346 April 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/346/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 12 Apr 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 2 April 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-2>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 58 March–April 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/58/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 3 Pages: i-iv, 161-255 March 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 10 Pages 2495-2728 (11 April 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/9>

Commentaries

Discussion Abstract only

[Rabies vaccination of the Maxakali indigenous population](#)

Dilceu Silveira Tolentino Júnior, Maryana Santos Vasconcelos Marques, Roberto Carlos de Oliveira
Pages 2495-2498

select article Enhancing clinical management of complex adverse events following immunization (AEFIs): A call for patient-centered solutions

Discussion

[Enhancing clinical management of complex adverse events following immunization \(AEFIs\): A call for patient-centered solutions](#)

Tiff-Annie Kenny

Pages 2499-2502

Review article Abstract only

[Reverse engineering protection: A comprehensive survey of reverse vaccinology-based vaccines targeting viral pathogens](#)

Saravanaraman Ponne, Rajender Kumar, S.M. Vanmathi, Raimunda Sâmia Nogueira Brilhante, Chinnadurai Raj Kumar

Pages 2503-2518

Research article Open access

[SimSAARlabim study – The role magic tricks play in reducing pain and stress in children](#)

Jutta Teichfischer, Regine Weber, Elisabeth Kaiser, Martin Poryo, ... Sascha Meyer

Pages 2572-2577

Research article Open access

[The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial](#)

Laura K. McCosker, Robert S. Ware, Holly Seale, Dona Hooshmand, ... Martin J. Downes

Pages 2578-2584

Research article Abstract only

[Do boys have the same intentions to get the HPV vaccine as girls? Knowledge, attitudes, and intentions in France](#)

Catherine Juneau, Estelle Fall, Julie Bros, Anne-Sophie Le Duc-Banaszuk, ... Aurélie Gauchet

Pages 2628-2636

Research article Abstract only

[Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study](#)

Noura El Salibi, Sawsan Abdulrahim, Maria El Haddad, Berthe Abi Zeid, ... Stephen J. McCall

Pages 2646-2654

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 12 Apr 2024]

Open Access Editorial

[Vaccine Efficacy, Impact, Hesitancy, and Acceptance: Trends for Public Health](#)

by Elias A. Said, Alessandra Noto, Sylvain Cardinaud and Ali A. Al-Jabri

Vaccines 2024, 12(4), 406; <https://doi.org/10.3390/vaccines12040406> - 11 Apr 2024

Abstract

Vaccines are indispensable tools in the battle against infectious diseases and hold great potential in combating a myriad of other diseases...

Value in Health

April 2024 Volume 27 Issue 4 p383-542

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 176 April 2024

<https://www.sciencedirect.com/journal/world-development/vol/176/suppl/C>

[Reviewed earlier]

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 12 Apr 2024]

Selected Research

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 12 Apr 2024]

[Filter: All articles]

[Red Teaming Large Language Models in Medicine: Real-World Insights on Model Behavior](#)

Crystal T. Chang, et al.

medRxiv 2024.04.05.24305411; doi: <https://doi.org/10.1101/2024.04.05.24305411>

Abstract

Background The integration of large language models (LLMs) in healthcare offers immense opportunity to streamline healthcare tasks, but also carries risks such as response accuracy and bias perpetration. To address this, we conducted a red-teaming exercise to assess LLMs in healthcare and developed a dataset of clinically relevant scenarios for future teams to use.

Methods We convened 80 multi-disciplinary experts to evaluate the performance of popular LLMs across multiple medical scenarios. Teams composed of clinicians, medical and engineering students, and technical professionals stress-tested LLMs with real world clinical use cases. Teams were given a framework comprising four categories to analyze for inappropriate responses: Safety, Privacy, Hallucinations, and Bias. Prompts were tested on GPT-3.5, GPT-4.0, and GPT-4.0 with the Internet. Six medically trained reviewers subsequently reanalyzed the prompt-response pairs, with dual reviewers for each prompt and a third to resolve discrepancies. This process allowed for the accurate identification and categorization of inappropriate or inaccurate content within the responses.

Results There were a total of 382 unique prompts, with 1146 total responses across three iterations of ChatGPT (GPT-3.5, GPT-4.0, GPT-4.0 with Internet). 19.8% of the responses were labeled as inappropriate, with GPT-3.5 accounting for the highest percentage at 25.7% while GPT-4.0 and GPT-4.0 with internet performing comparably at 16.2% and 17.5% respectively. Interestingly, 11.8% of responses were deemed appropriate with GPT-3.5 but inappropriate in updated models, highlighting the ongoing need to evaluate evolving LLMs.

Conclusion The red-teaming exercise underscored the benefits of interdisciplinary efforts, as this collaborative model fosters a deeper understanding of the potential limitations of LLMs in healthcare and sets a precedent for future red teaming events in the field. Additionally, we present all prompts and outputs as a benchmark for future LLM model evaluations.

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 12 Apr 2024]

Selected Research

Study Protocol Open Access

[Social, Ethical and Regulatory implications of conducting a malaria Vaccine Efficacy trial in a human infection study in Kenya \(SERVE-Kenya\): A study protocol](#)

[version 1; peer review: awaiting peer review]

Primus Che Chi, et al. and Members of the VAC074 Study Team

Abstract

Malaria remains an important public health problem in many LMICs, including Kenya – necessitating alternative prevention and control strategies. Malaria human infection studies (HIS) – trials that involve the deliberate infection of healthy volunteers with malaria parasites to assess the efficacy of potential vaccine and drug candidates and to understand the innate and acquired protection against malaria parasites - have become an important approach to fast-track the development of a malaria vaccine. The KEMRI-Wellcome Trust Research Programme (KWTRP) otherwise known as the KEMRI Centre for Geographic Medicine Research (Coast) (KEMRI CGMRC) has developed expertise in setting up and running research on malaria HIS, with two completed and two planned in the coming months. One of the planned studies is an EDCTP-funded Phase IIb malaria vaccine efficacy trial within a HIS. While all scientific proposals at KWTRP are carefully reviewed by national and

international science and ethics review bodies and are supported by a well-developed local community engagement platform, research to understand the social, ethical and regulatory issues for HIS from a grounded perspective is in early stages of development, especially in LMICs. Given the particular opportunities provided by the KWTRP's experience in running HIS, expertise in embedded social science research and the presence of a well-established community engagement platform, we plan to conduct a social science study within the HIS-based Phase IIb malaria vaccine trial. The overall aim is to contribute to the development of locally responsive policies on the ethical conduct of malaria vaccine efficacy studies involving the use of a HIS in Kenya. Data will be collected from a range of HIS stakeholders, including HIS participants, community members, HIS research team, ethics committees, regulatory authorities and policy makers through surveys, interviews, group discussions, participatory workshops, observations and document review. This is an EDCTP-funded Career Development Fellowship project awarded to PCC.

Open Letter Open Access

[Southeast Asia initiative to combat SARS-CoV-2 variants \(SEACOVARIANTS\) consortium](#)

[version 1; peer review: awaiting peer review]

Le Nguyen Truc Nhu, et al and the SEACOVARIANTS Consortium

Abstract

A strong and effective COVID-19 and future pandemic responses rely on global efforts to carry out surveillance of infections and emerging SARS-CoV-2 variants and to act accordingly in real time. Many countries in Southeast Asia lack capacity to determine the potential threat of new variants, or other emerging infections. Funded by Wellcome, the Southeast Asia initiative to combat SARS-CoV-2 variants (SEACOVARIANTS) consortium aims to develop and apply a multidisciplinary research platform in Southeast Asia (SEA) for rapid assessment of the biological significance of SARS-CoV-2 variants, thereby informing coordinated local, regional and global responses to the COVID-19 pandemic. Our proposal is delivered by the Vietnam and Thailand Wellcome Africa Asia Programmes, bringing together a multidisciplinary team in Indonesia, Thailand and Vietnam with partners in Singapore, the UK and the USA. Herein we outline five work packages to deliver strengthened regional scientific capacity that can be rapidly deployed for future outbreak responses.

* * * *

[Think Tanks](#)

Brookings [to 12 Apr 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 12 Apr 2024]

<https://www.cgdev.org/>

All Research [Selected]

POLICY PAPERS

[Beyond the "Gavi-Eligible": High-Leverage Opportunities for Gavi to Enhance Vaccine Access and Uptake in Ineligible Middle-Income Countries](#)

[Rachel Silverman Bonnifield et al.](#)

April 08, 2024

The global locus of undervaccination is increasingly shifting from the poorest countries in the world—which are eligible for support from Gavi, the Vaccine Alliance (Gavi)—to middle-income

countries (MICs) that do not qualify for traditional Gavi support. Given these growing challenges, Gavi must rethink its engagement with those MICs that are ineligible for traditional support. Although this engagement is intended to be “catalytic” and has been intentionally targeted to country needs, it also has been relatively small-scale and ad hoc. Gavi’s next five-year strategic period from 2026 to 2030, known as “Gavi 6.0,” offers a window of opportunity for its board and leadership to consider new and different ways for Gavi to engage with MICs to advance global vaccine access and improve vaccination outcomes. To have the greatest impact in this context, Gavi must lean into its comparative advantage in market shaping and demand consolidation to drive its contributions to global vaccination efforts with finite resources. We offer recommendations for Gavi to operationalize broader engagement with MICs, specifically by enabling an expanded cohort of MICs to access more affordable prices for both newer, costlier vaccines and future vaccines via opt-in framework agreements and by supporting a global coordinating hub to shape a forward-looking immunization innovation agenda.

Chatham House [to 12 Apr 2024]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 12 Apr 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 12 Apr 2024]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 12 Apr 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

[**Long COVID Rates Appear to be Stabilizing, Affecting About 1 in 10 Adults Who Have Had COVID**](#) April 9, 2024 News Release

Rates of long COVID have begun to flatten. About 1 in 10 adults with COVID have reported having long COVID since rates fell in 2023, according to a KFF analysis of the latest data from the Centers for Disease Control and Prevention. If the rate continues to hold steady, new...

McKinsey Global Institute [to 12 Apr 2024]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 12 Apr 2024]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 12 Apr 2024]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 12 Apr 2024]

<https://www.rand.org/pubs.html>

Published Research [Selected]

No new digest content identified.

Urban Institute [to 12 Apr 2024]

<https://www.urban.org/publications>

New Research Publications - Selected

Essay

Understanding the Crisis in Institutional Trust

April 9, 2024

Institutions are patterns of relationship. They form essential threads of our social contract. But those threads are fraying. In the United States, individuals' trust in major institutions has declined 22 percentage points since 1979.

Institutions face a range of profound challenges. A long-overdue reckoning with the history of racial injustice has highlighted how many institutions reflect patterns of inequity. Technology platforms have supercharged access to information but also reinforced bubbles of interpretation. Anti-elite sentiment has evolved into anti-institutional rebellion.

These forces are affecting institutions of all kinds—from disciplines like journalism to traditions like the nuclear family. This essay focuses on a particular type of institution: organizations. The decline in trust in organizations has practical implications: trust is essential to the day-to-day work of an organization—whether an elite university, a traffic court, or a corner store. The stakes for society are hard to overstate. Organizations “organize” much of our society, culture, and economy.

This essay is meant to offer background for ongoing conversations about the crisis in institutional trust. It does not claim to offer a solution; instead, it lays out the parts of the problem as a step toward shared solutions...

World Economic Forum [to 12 Apr 2024]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....

.....

Public Consultations/Call for Inputs/Call for Papers

Invitation for Public Comment: WHO principles for human genome access, use and sharing

8 April 2024 **Consultation Period: 8th April 2024 – 3 May 2024**

Background:

For the potential of genomics to be realized, access to, use, and the sharing of human genome data is critical. Following the WHO's Science Council 2022 Report on Accelerating access to genomics for global health: promotion, implementation, collaboration, and ethical, legal, and social issues, WHO is implementing a programme of activities to promote equitable and fair access to genomics technologies for the benefit of people worldwide. As part of this, WHO is developing guiding principles for human genome data access, use and sharing. To develop these principles, a virtual consultation was held in January 2024 with an interdisciplinary group of participants. This consultation discussed the diverse perspectives on issues related to human genome data access, use and sharing; how a global set of principles from WHO may enable data access, use and sharing; and proposed initial principles. This was followed by an in-person meeting in March 2024 that considered in detail the proposed principles. Following this meeting, a draft document was developed and comments on this document and the principles are now invited.

Feedback on the WHO Principles for human genome data access, use, and sharing Public feedback on this document is being solicited through this public consultation using the [comment form](#).

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *